VIDEO: Future of lung cancer treatment lies in targeted immunotherapy

ByRoy Herbst, MD, PhD

In this video, Roy S. Herbst, MD, PhD, associate cancer center director for translational research at Yale Cancer Center, described findings from the PIONeer study, which was developed through a public-private partnership in France.

Herbst, who also serves as ensign professor of medicine and professor of pharmacology, and chief of medical oncology at Yale Cancer Center and Smilow Cancer Hospital, explained that the PIONeeR researchers analyzed tissue of patients with late or early disease progression following immunotherapy treatment to identify biomarkers that could possibly predict who would and would not benefit from immunotherapy.

“This was a fantastic study and something we need to do,” he said. “That’s the future: targeted immunotherapy.”

References:

Barlesi F, et al. Abstract LBA53. Presented at: European Society for Medical Oncology Virtual Congress 2020; Sept. 19-21, 2020.

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interview

Disclosures: Herbst reports receiving research support from AstraZeneca, Eli Lilly and Company, Genentech/Roche and Merck and Company, and serving as a board member for Junshi Pharmaceuticals and as a consultant for AbbVie Pharmaceuticals, ARMO Biosciences, AstraZeneca, Biodesix, Bolt Biotherapeutics, Bristol‐Myers Squibb, Cybrexa, Eli Lilly and Company, EMD Serono, Genentech/Roche, Genmab, Halozyme, Heat Biologics, IMAB Biopharma, Immunocore, Infinity Pharmaceuticals, Loxo Oncology, Merck and Company, Mirati Therapeutics, Nektar, Neon Therapeutics, NextCure, Novartis, Pfizer, Sanofi, Seattle Genetics, Shire PLC, Spectrum Pharmaceuticals, Symphogen, Takeda, Tesaro, Tocagen and WindMIL Therapeutics.

Take Homes in Lung Cancer

Read more

VIDEO: Future of lung cancer treatment lies in targeted immunotherapy

References:

Related Content